NPIL increases its custom manufacturing offering
Nicholas Piramal India Limited has signed a deal to purchase Healthline Private Ltd's (HLPL) pharmaceuticals business for a consideration of Rs150m (
Nicholas Piramal India Limited has signed a deal to purchase Healthline Private Ltd's (HLPL) pharmaceuticals business for a consideration of Rs150m (£1.92m).
HLPL has a modern manufacturing unit at Bangalore for small and large volume injectables. The current facility has capacity of 10 million vials per annum.
With assets across North America, UK and India, NPIL Pharma offers development and commercial scale manufacture services in both API and formulations. The company plans to invest additional resources at the HLPL facility to expand capacity and to secure US FDA inspection approval.
NPIL's recent acquisition of the former Pfizer site at Morpeth places NPIL among the leading custom manufacturing organisations. The Morpeth site manufactures a number of finished APIs and currently supplies over 300 finished dosage forms SKUs (stock keeping units) to over 100 markets including US, Europe and Japan.
The company is investing further in high potency API production and has added a sixth suite for the cGMP manufacture of antibody based drug conjugates. This is due on stream in the first quarter of 2008.
